Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gsk2816126. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 known ✓ | Q15910 | 17/20 | 1.00 |
| ▸ | EZH1 | Q92800 | 6/20 | 1.00 |
| ▸ | EED | O75530 | 3/20 | 1.00 |
| ▸ | SUZ12 | Q15022 | 3/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.80 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.75 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.62 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.62 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk2816126 SCHEMBL2595737 | 1.00 | EZH2 (1.00) | EZH2EZH1EEDSUZ12HDAC1 | |
| Gsk2816126 SCHEMBL29352969 | 1.00 | EZH2 (1.00) | EZH2EZH1EEDSUZ12HDAC1 | |
| Gsk2816126 SCHEMBL12180401 | 1.00 | EZH2 (1.00) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL14933215 | 0.94 | EZH2 (0.90) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL19033201 | 0.94 | EZH2 (0.88) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL29308159 | 0.94 | EZH2 (0.88) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL18768926 | 0.94 | EZH2 (0.88) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL2594075 | 0.94 | EZH2 (1.00) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL14726866 | 0.93 | EZH2 (0.88) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL14726845 | 0.93 | EZH2 (0.88) | EZH2EZH1EEDSUZ12HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335452-A1 | COMPOSITIONS AND METHODS OF COMBINATION THERAPY FOR TARGETING LYMPHOMA | CULLGEN (SHANGHAI), INC. (CN) | 2024-10-10 | — | — | US | claimed |
| US-12036222-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor | The Wistar Institut of Anatomy and Biology (US) | 2024-07-16 | — | — | US | claimed |
| CN-118201612-A | Compositions and methods for combination therapy for the treatment of lymphomas | 上海睿跃生物科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| US-11992500-B2 | Use of methylation inhibitors for the treatment of autoimmune diseases | RUSH UNIVERSITY MEDICAL CENTER (US) | 2024-05-28 | — | — | US | claimed |
| CN-114144230-B | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | 弗尔康医疗公司 | 2024-04-23 | — | — | CN | claimed |
| EP-3823671-B1 | INHIBITION OF PRC2 SUBUNITS TO TREAT EYE DISORDERS | FOND ASILE DES AVEUGLES (CH) | 2024-02-07 | — | — | EP | claimed |
| EP-3990444-A1 | USE OF INHIBITORS OF ENHANCER OF ZESTE HOMOLOG 2 | The Board of Regents of The University of Texas System (US) | 2022-05-04 | — | — | EP | claimed |
| CN-114144230-A | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | 弗尔康医疗公司 | 2022-03-04 | — | — | CN | claimed |
| EP-3938050-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | claimed |
| US-20210251987-A1 | Methods of Treating Cancers Overexpressing Carm1 With EZH2 Inhibitors and Platinum-Based Antineoplastic Drugs | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-08-19 | — | — | US | claimed |
| US-20160340674-A1 | Compositions and Methods to Inhibit EZH2 for the Treatment of Cardiovascular Diseases | UNIVERSITY OF ROCHESTER | 2016-11-24 | — | — | US | claimed |
| EP-2773754-B1 | Compounds for use in the treatment of T-cell mediated diseases | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-08-03 | — | — | EP | claimed |
| US-9402836-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2016-08-02 | — | — | US | claimed |
| US-20150313887-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2015-11-05 | — | — | US | claimed |
| WO-2015120372-A2 | COMPOSITIONS AND METHODS TO INHIBIT EZH2 FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | UNIVERSITY OF ROCHESTER (US) | 2015-08-13 | — | — | WO | claimed |
| US-8975291-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2015-03-10 | — | — | US | claimed |
| US-20130345200-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2013-12-26 | — | — | US | claimed |
| EP-2566327-A1 | INDOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | claimed |
| CN-102970869-A | Indoles | GLAXOSMITHKLINE LLC | 2013-03-13 | — | — | CN | claimed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210251987-A1 | Methods of Treating Cancers Overexpressing Carm1 With EZH2 Inhibitors and Platinum-Based Antineoplastic Drugs | CARM1, EZH2, PRMT1 | EZH2 2/4885EZH1 16/4885EED 17/4885 |
| US-20240335452-A1 | COMPOSITIONS AND METHODS OF COMBINATION THERAPY FOR TARGETING LYMPHOMA | EZH2, BCL6, BMI1 | EZH2 1/4885EZH1 14/4885EED 18/4885 |
| US-20150313887-A1 | INDOLES | IDO1, IDO2, INMT | EZH2 257/4885EZH1 669/4885EED 3322/4885 |
| US-20130345200-A1 | INDOLES | IDO1, IDO2, INMT | EZH2 257/4885EZH1 669/4885EED 3322/4885 |
| US-20160340674-A1 | Compositions and Methods to Inhibit EZH2 for the Treatment of Cardiovascular Diseases | EZH2, BMI1, EED | EZH2 1/4885EZH1 4/4885EED 3/4885 |
| US-12036222-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor | CARM1, EZH2, PRMT1 | EZH2 2/4885EZH1 31/4885EED 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.